Uropathogenic E. coli induces DNA damage in the bladder.


Journal

PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921

Informations de publication

Date de publication:
02 2021
Historique:
received: 30 09 2020
accepted: 13 01 2021
entrez: 25 2 2021
pubmed: 26 2 2021
medline: 24 6 2021
Statut: epublish

Résumé

Urinary tract infections (UTIs) are among the most common outpatient infections, with a lifetime incidence of around 60% in women. We analysed urine samples from 223 patients with community-acquired UTIs and report the presence of the cleavage product released during the synthesis of colibactin, a bacterial genotoxin, in 55 of the samples examined. Uropathogenic Escherichia coli strains isolated from these patients, as well as the archetypal E. coli strain UTI89, were found to produce colibactin. In a murine model of UTI, the machinery producing colibactin was expressed during the early hours of the infection, when intracellular bacterial communities form. We observed extensive DNA damage both in umbrella and bladder progenitor cells. To the best of our knowledge this is the first report of colibactin production in UTIs in humans and its genotoxicity in bladder cells.

Identifiants

pubmed: 33630958
doi: 10.1371/journal.ppat.1009310
pii: PPATHOGENS-D-20-02156
pmc: PMC7906301
doi:

Substances chimiques

Mutagens 0
Peptides 0
Polyketides 0
colibactin 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1009310

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Microb Pathog. 2012 Sep;53(3-4):180-2
pubmed: 22709536
J Infect Dis. 2014 Jul 15;210(2):285-94
pubmed: 24489107
Infect Immun. 2015 Sep;83(9):3704-11
pubmed: 26150540
J Am Chem Soc. 2014 Jul 2;136(26):9244-7
pubmed: 24932672
Pathogens. 2016 Jan 15;5(1):
pubmed: 26784237
Nat Commun. 2019 Jul 19;10(1):3224
pubmed: 31324782
PLoS One. 2013 Oct 08;8(10):e77157
pubmed: 24116215
J Clin Microbiol. 2010 Jun;48(6):2122-9
pubmed: 20375237
Cell Rep. 2018 Oct 9;25(2):464-477.e4
pubmed: 30304685
Proc Natl Acad Sci U S A. 2004 Feb 3;101(5):1333-8
pubmed: 14739341
Science. 2019 Feb 15;363(6428):
pubmed: 30765538
Bladder Cancer. 2016 Jan 7;2(1):37-47
pubmed: 27376123
Proc Natl Acad Sci U S A. 2010 Jun 22;107(25):11537-42
pubmed: 20534522
Infect Immun. 1990 May;58(5):1281-9
pubmed: 2182540
J Biol Chem. 2011 Oct 14;286(41):35562-35570
pubmed: 21795676
Nat Rev Microbiol. 2015 May;13(5):269-84
pubmed: 25853778
Gut. 2014 Dec;63(12):1932-42
pubmed: 24658599
Acta Paediatr Scand. 1975 May;64(3):432-6
pubmed: 1098383
Med Sci (Basel). 2020 Mar 13;8(1):
pubmed: 32183076
Nature. 2020 Apr;580(7802):269-273
pubmed: 32106218
Nat Rev Microbiol. 2020 Apr;18(4):211-226
pubmed: 32071440
EcoSal Plus. 2009 Aug;3(2):
pubmed: 26443763
PLoS Pathog. 2019 Sep 23;15(9):e1008029
pubmed: 31545853
PLoS One. 2013;8(2):e56964
pubmed: 23457644
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Br J Cancer. 2015 Feb 3;112(3):594-600
pubmed: 25429525
FEMS Immunol Med Microbiol. 2009 Oct;57(1):69-79
pubmed: 19678844
J Am Chem Soc. 2013 Mar 6;135(9):3359-62
pubmed: 23406518
Proc Natl Acad Sci U S A. 2012 Feb 7;109(6):2078-83
pubmed: 22308455
J Clin Microbiol. 2008 Aug;46(8):2529-34
pubmed: 18495863
Nat Chem. 2019 Oct;11(10):880-889
pubmed: 31527851
Science. 2019 Sep 6;365(6457):
pubmed: 31395743
PLoS Biol. 2018 Jul 3;16(7):e2005970
pubmed: 29969450
Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6640-5
pubmed: 10829079
Toxicol Appl Pharmacol. 2009 Oct 1;240(1):8-14
pubmed: 19538980
Gut Microbes. 2014;5(5):675-80
pubmed: 25483338
mBio. 2018 Mar 20;9(2):
pubmed: 29559578
Infect Immun. 2012 Feb;80(2):668-78
pubmed: 22104113
PLoS Pathog. 2010 Aug 12;6(8):e1001042
pubmed: 20811584
Infect Immun. 2001 Jul;69(7):4572-9
pubmed: 11402001
Nat Rev Microbiol. 2010 Mar;8(3):207-17
pubmed: 20157339
Mar Drugs. 2016 Apr 16;14(4):
pubmed: 27092515
PLoS Pathog. 2015 Jan 08;11(1):e1004599
pubmed: 25569799
EcoSal Plus. 2018 Apr;8(1):
pubmed: 29667573
Science. 2018 Feb 2;359(6375):592-597
pubmed: 29420293
Nat Commun. 2016 Jun 20;7:11914
pubmed: 27320313
Nat Med. 2020 Jul;26(7):1063-1069
pubmed: 32483361
Urology. 2011 Jun;77(6):1420-5
pubmed: 21459419
Nat Commun. 2017 Nov 3;8(1):1314
pubmed: 29101366
Science. 2012 Oct 5;338(6103):120-3
pubmed: 22903521
Science. 2006 Aug 11;313(5788):848-51
pubmed: 16902142
J Am Chem Soc. 2019 Jul 24;141(29):11489-11496
pubmed: 31251062
Microbes Infect. 2020 Apr;22(3):144-147
pubmed: 31954842
PLoS Pathog. 2013;9(7):e1003437
pubmed: 23853582
Nat Protoc. 2009;4(8):1230-43
pubmed: 19644462
Curr Opin Microbiol. 2013 Feb;16(1):100-7
pubmed: 23403118
PLoS One. 2012;7(11):e50020
pubmed: 23209633

Auteurs

Camille V Chagneau (CV)

IRSD, INSERM, Université de Toulouse, INRA, ENVT, UPS, Toulouse, France.

Clémence Massip (C)

IRSD, INSERM, Université de Toulouse, INRA, ENVT, UPS, Toulouse, France.
CHU Toulouse, Hôpital Purpan, Service de Bactériologie-Hygiène, Toulouse, France.

Nadège Bossuet-Greif (N)

IRSD, INSERM, Université de Toulouse, INRA, ENVT, UPS, Toulouse, France.

Christophe Fremez (C)

VibioSphen, Prologue Biotech, Labège, France.

Jean-Paul Motta (JP)

IRSD, INSERM, Université de Toulouse, INRA, ENVT, UPS, Toulouse, France.

Ayaka Shima (A)

IRSD, INSERM, Université de Toulouse, INRA, ENVT, UPS, Toulouse, France.

Céline Besson (C)

IRSD, INSERM, Université de Toulouse, INRA, ENVT, UPS, Toulouse, France.

Pauline Le Faouder (P)

MetaToulLipidomics Facility, INSERM UMR1048, Toulouse, France.

Nicolas Cénac (N)

IRSD, INSERM, Université de Toulouse, INRA, ENVT, UPS, Toulouse, France.

Marie-Paule Roth (MP)

IRSD, INSERM, Université de Toulouse, INRA, ENVT, UPS, Toulouse, France.

Hélène Coppin (H)

IRSD, INSERM, Université de Toulouse, INRA, ENVT, UPS, Toulouse, France.

Maxime Fontanié (M)

VibioSphen, Prologue Biotech, Labège, France.

Patricia Martin (P)

IRSD, INSERM, Université de Toulouse, INRA, ENVT, UPS, Toulouse, France.
VibioSphen, Prologue Biotech, Labège, France.

Jean-Philippe Nougayrède (JP)

IRSD, INSERM, Université de Toulouse, INRA, ENVT, UPS, Toulouse, France.

Eric Oswald (E)

IRSD, INSERM, Université de Toulouse, INRA, ENVT, UPS, Toulouse, France.
CHU Toulouse, Hôpital Purpan, Service de Bactériologie-Hygiène, Toulouse, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH